Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Because of the fast growth, early hepatic metastasis and the multidrug resistance, the five-year survival rate is very low. Thus, the understanding of its biology can significantly contribute in identifying valuable targets for novel therapeutic approaches. In this regard, E2F1 may represent an interesting candidate. E2F1 is a transcription factor implicated in the regulation of many cellular processes including cell proliferation and apoptosis. Whereas the involvement of E2F1 in HCC has been recognized, its ability to act as a proliferative and/or apoptotic factor in HCC has not yet been clarified and, in this regard, an active debate is ongoing. The definition of E2F1 role in HCC is not a trivial aspect as it can have significant consequences for the development of novel therapeutic options with E2F1 as target. In this review, we present data about the reported proliferative/apoptotic effects as well as the dual (combined proliferation and apoptosis) functions of E2F1 in HCC discussing the molecular basis for this behavior. The data available so far indicate that the proliferative and apoptotic functions of E2F1 in HCC may coexist but the proliferative effect seems to be more pronounced than the apoptotic one.
Current Drug Delivery
Title:The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Volume: 14 Issue: 2
Author(s): Rossella Farra, Gabriele Grassi, Federica Tonon, Michela Abrami, Mario Grassi, Gabriele Pozzato, Nicola Fiotti, Giancarlo Forte and B. Dapas
Affiliation:
Keywords: Apoptosis, E2F1, HCC, miRNA, proliferation, p53.
Abstract: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Because of the fast growth, early hepatic metastasis and the multidrug resistance, the five-year survival rate is very low. Thus, the understanding of its biology can significantly contribute in identifying valuable targets for novel therapeutic approaches. In this regard, E2F1 may represent an interesting candidate. E2F1 is a transcription factor implicated in the regulation of many cellular processes including cell proliferation and apoptosis. Whereas the involvement of E2F1 in HCC has been recognized, its ability to act as a proliferative and/or apoptotic factor in HCC has not yet been clarified and, in this regard, an active debate is ongoing. The definition of E2F1 role in HCC is not a trivial aspect as it can have significant consequences for the development of novel therapeutic options with E2F1 as target. In this review, we present data about the reported proliferative/apoptotic effects as well as the dual (combined proliferation and apoptosis) functions of E2F1 in HCC discussing the molecular basis for this behavior. The data available so far indicate that the proliferative and apoptotic functions of E2F1 in HCC may coexist but the proliferative effect seems to be more pronounced than the apoptotic one.
Export Options
About this article
Cite this article as:
Farra Rossella, Grassi Gabriele, Tonon Federica, Abrami Michela, Grassi Mario, Pozzato Gabriele, Fiotti Nicola, Forte Giancarlo and Dapas B., The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma, Current Drug Delivery 2017; 14 (2) . https://dx.doi.org/10.2174/1567201813666160527141742
DOI https://dx.doi.org/10.2174/1567201813666160527141742 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic Ion Fluxes and Cancer (Guest Editors: Luca Munaron and Annarosa Arcangeli)]
Recent Patents on Anti-Cancer Drug Discovery Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Current Topics in Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Nanocarriers as Prospective Approach in Effective Management of Acne Vulgaris
Micro and Nanosystems Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Copper-62 Labeled ReCCMSH Peptide Analogs for Melanoma PET Imaging
Current Radiopharmaceuticals New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Sonoelastography for Pelvic Metastatic Malignant Pheochromocytoma: A Case Report
Current Medical Imaging PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Pharmacokinetic Distribution of 67Cu(II)2[3,5-Diisopropyl(Carboxy- 14C)Salicylate]4 Among Murine Tissues
Current Medicinal Chemistry